key: cord-0808740-njey640s
authors: Mohapatra, Ranjan K.; Tiwari, Ruchi; Sarangi, Ashish K.; Islam, Md. Rabiul; Chakraborty, Chiranjib; Dhama, Kuldeep
title: Omicron (B.1.1.529) variant of SARS‐CoV‐2: Concerns, challenges, and recent updates
date: 2022-02-12
journal: J Med Virol
DOI: 10.1002/jmv.27633
sha: 47d8f61002caaa34a5f9e7eb2f41c30ebff910a3
doc_id: 808740
cord_uid: njey640s

Omicron has shown immune escape from neutralizing antibodies generated through previous infection or vaccination. It could evade the protection provided by mAbs being used in clinics for treating coronavirus disease 2019 (COVID‐19) patients. Booster dose is recommended to elevate the protective levels of antibodies in COVID‐19 vaccinated individuals. The development of powerful oral antiviral drugs such as Molnupiravir and Paxlovid have shown promising clinical results and raised new hopes of COVID‐19 treatment. High efforts are being made to develop highly efficacious vaccines, and by implementing appropriate prevention and control strategies to counter Omicron.

Delta cases than reported as of now. Real-time spread of Omicron needs to be tracked with molecular data. 12 The variants such as Alpha, Delta, and Omicron have high transmissibility. 5, 10 Soon after the emergence of the Omicron variant, a very rapid and high surge in COVID-19 cases on a daily basis is being observed worldwide with cumulative cases crossing the mark of 350 million confirmed cases and over 5.6 million deaths as of January 24, 2022. Notably, more than 3.5 million cases are being reported per day that is adding to an ever higher peak during the ongoing pandemic. 5, 8, 9, 13, 14 The Omicron variant is found more contagious but less deadly than the Delta variant. The main clinical manifestations are those of a "mild infection" such as headache, body ache, muscles ache, cough, fever, generalized myalgia, and fatigue, therefore hospital admission is less likely but a higher transmission rate of Omicron will be a major concern. 9, [15] [16] [17] [18] [19] Mutations in the receptor-binding domain (RBD) of the Omicron variant's spike (S) protein result in a stronger binding to the human ACE2 receptor, through which the virus gains entry into the cells of the body. The relatively effective reproduction number of this variant has been reported to be 3.19 (95% confidence interval 2.82-3.61) times greater than the Delta variant. Therefore, a rapid increase in Omicron cases is being witnessed across the globe immediately after its introduction to any country due to the considerable advantage of higher transmissibility and infectivity. [19] [20] [21] More recently, some news has come up with regard to the possibility of a highly transmissible SARS-CoV-2 double variant (Delmicron), sus- did not spread. 29 However, the study was conducted as of November 1, 2021, hence, more recent studies on genome sequences are required to understand such situations of concern in a better way.

Additionally, simultaneous infection of COVID-19 and flu has been reported more recently in a young pregnant woman from Israel and has been given the name "Flurona." [25] [26] [27] As per the report, the young woman was COVID-19 unvaccinated and the copresence of both the pathogens (Flu virus and SARS-CoV-2) was detected in her body. The simultaneous infection of COVID-19 and influenza A (H1N1) virus was also confirmed earlier in a 21-year-old woman in Egypt. 30 Due to the simultaneous attack of two viruses, the body's immunity system may be compromised. As per WHO, a person may be infected by both the strains (COVID-19 and influenza) at the same time which could be catastrophic to the immune system. 31 Such simultaneous attacks of flu and COVID-19 may cause more respiratory failure and damage to other organs. As per CDC, COVID-19 and flu can attack simultaneously to the lungs and potentially cause pneumonia, and finally respiratory failure. 32 This may also cause cardiac injury, sepsis, and inflammation of the brain, heart, and (or) muscle tissues. 32 surveillance. This variant was found in 12 people in the country and hasn't posed much of a threat yet. 28 However, it is highly recommended to understand its rate of infectivity and the risk of vaccine-induced immunity. The first IHU infected patient has a travel history to Cameroon. 33 This variant has not been identified in other countries yet. As per a recent study, fourteen amino acid substitutions with N501Y and E484K are located in the 'S' protein of the IHU variant. Both N501Y and E484K mutations were also seen earlier in Beta, Gamma, Theta, and Omicron variants. 34 (Table 1) . Omicron can also overpower the protection rendered by antibodies-based immunotherapies through escaping the neutralization potential of therapeutic monoclonal antibodies (mABs), therefore some mAbs currently available for use in clinics may lose efficacy and will not be useful in treating Omicron-infected patients (Table 1) Early and rapid detection, strengthening of genomic surveillance, tracking, and monitoring, and contact tracing of variant infected individuals need to be given due attention. 85 Enhancing COVID-19 vaccination campaigns and booster doses of vaccines, updating current vaccines, and developing highly effective newer vaccines to keep pace against the emergence of variants are the basic needs to counter Omicron. 86, 87 Considering the potential benefit of booster vaccines, the third dose as a booster shot is necessarily required to facilitate vigorous neutralizing antibody responses against Omicron. 63, 65, 68 Of note, amidst the threats of highly evolving SARS-CoV-2 with its newer variants coming up continuously, the currently available vaccines are not being proven as silver bullets and neither mAbs are acting as magic bullets for prevention and treatment purposes. In such an adverse situation, newer strategies to develop next-generation mutation-proof SARS-CoV-2 vaccines and designing more effective and additional mAbs are required that would be more robust in countering highly mutated variants. Additionally, exploring more effective drugs and treatable options are the need of the hour. [77] [78] [79] 88, 89 The airborne transmission and extensive environmental con- Anti-NTD and anti-RBD monoclonal antibodies (mAbs), bamlanivimab, Imdevimab), broadly neutralizing sarbecovirus mAbs, cocktails 35, 36 Negligible neutralization effect 35 Some neutralization effect 36 Non-RBD Abs 37 Almost no neutralizing effect 37 Almost no neutralizing effect Convalescent sera 35 Four to six-fold less effective neutralizing antibodies 35 More than eight-fold reduction in neutralizing antibodies 38 One-dose ChAdOx1 (Oxford/AstraZeneca) 35 Almost no neutralizing effect 35 Almost no neutralizing effect 39 Two-doses of ChAdOx1 (Oxford/AstraZeneca) vaccine 35 Considerable neutralization effect/protection 35 Almost no neutralizing effect 39 Two-dose of ChAdOx1 (Oxford/AstraZeneca) vaccinees 37 Some neutralization effect 37, 40 Almost no neutralizing effect 39 Two-dose of BNT162b2 (Pfizer/BioNTech) vaccinees and CoronaVac (Sinovac) 37, 41, 42 Better neutralization effect as compared to ChAdOx1 vaccinees, 37 some neutralization effect, 41 can still cause breakthrough infections 41 Some/no neutralization effect 42 More than 40-fold reduction in neutralizing antibodies 43 One-dose Ad26.COV2.S vaccine (Johnson & Johnson-Janssen) 44 Almost no neutralizing effect 44 Almost no neutralizing effect 44 2-dose of ChAdOx1 (Oxford/AstraZeneca), BNT162b2 (Pfizer/BioNTech), mRNA-1273 (Moderna), NVX-CoV2373 vaccine (Novavax), other mRNA vaccines 45, 46 Asymptomatic and mild infections 45 Some neutralization effect 44, 47 More than eight-fold reduction in neutralizing antibodies 38 Only 17% protection against infection 46 Booster dose after 6-months with mRNA-1273 (Moderna), and CoronaVac/PiCoVacc (Sinovac) and other mRNA based vaccines 45, 48 Considerable neutralization effect/protection 45 Considerable neutralization effect/protection 44, 47, 48 Infected people who later took a single dose of mRNA vaccination 39, 45 Considerable neutralization effect/protection 45 Some neutralization effect 39, 44 BNT162b2 (Pfizer/BioNTech) vaccinees later infected with Delta variant 39, 49 Considerable neutralization effect/protection 49 Some neutralization effect 39, 44 Infected and later completed 3-doses of mRNA vaccination 44 Considerable neutralization effect/protection 44 Mankind may be forced to live with COVID-19, therefore vaccination campaigns will need to continue, appropriate routine behavioral changes will become more and more vital for adopting safety measures and other necessary disease prevention and control measures as the "new normal" lifestyle of the modern world.

WHO COVID-19 Dashboard -Up to date data on pandemic

Geneva Centre for Emerging Viral Diseases. Novel SARS-CoV-2 variants: the pandemics within the pandemic

Tracking of variants

Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe

World Health Organization. Tracking SARS-CoV-2 variants

WHO. DRAFT landscape of COVID-19 candidate vaccines

Omicron (B.1.1.529) -variant of concern -molecular profile and epidemiology: a mini review

Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics

Omicron (B.1.1.529 variant of SARS-CoV-2); an emerging threat: current global scenario

Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern

Track Omicron's spread with molecular data

Winter of Omicron-the evolving COVID-19 pandemic

Worldmeter COVID-19 Coronavirus pandemic

Covid-19: Early studies give hope omicron is milder than other variants

Covid-19: Omicron is causing more infections but fewer hospital admissions than delta, South African data show

Covid-19: Runny nose, headache, and fatigue are commonest symptoms of omicron, early data show

Covid-19: Hospital admission 50-70% less likely with omicron than delta, but transmission a major concern

Omicron variant (B.1.1.529): infectivity, vaccine breakthrough, and antibody resistance

Relative instantaneous reproduction number of Omicron SARS-CoV-2 variant with respect to the Delta variant in Denmark

Mutations on RBD of SARS-CoV-2 Omicron variant result in stronger binding to human ACE2 receptor

What exactly is 'Delmicron'? Scientists warn of super strain -Here's all about its origin, mutation, etc

Bhalla), Delta plus Omicron are driving COVID surge now, know symptoms, mortality rate

Delmicron', it's 'flurona': Israel reports first double infection of Covid and flu

All you need to know about Florona: A double infection of flu and COVID-19

From Delmicron to flurona: Israel reports first double infection of Covid and flu

Official Downplays New COVID IHU Variant Found in France

Study claims 'Delmicron' threat less likely for now

Coinfection with SARS-CoV-2 and influenza A(H1N1) in a patient seen at an influenza-like illness surveillance site in Egypt: case report

WHO. Coronavirus disease (COVID-19): Similarities and differences between COVID-19 and Influenza

Yes, you can have Covid-19 and the flu at the same time. Here's what that could look like

The Times of India, France detects new Covid variant IHU, 12 infected

Emergence in Southern France of a new SARS-CoV-2 variant of probably Cameroonian 5 origin harbouring both substitutions N501Y and E484K in the spike protein

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination

The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron

SARS-CoV-2 Omicron variant neutralization in serum from vaccinated and convalescent persons

SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion

Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians

Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients

SARS-CoV-2 omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection

Plasma neutralization of the SARS-CoV-2 Omicron variant

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis

Epidemiological characterisation of the first 785 SARS-CoV-2 Omicron variant cases in Denmark

Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

Antibody response and variant cross-neutralization after SARS-CoV-2 breakthrough infection

Heterologous prime-boost strategies for COVID-19 vaccines

In vitro data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion

Omicron likely to weaken COVID vaccine protection

Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. bioRxiv

The challenges of COVID-19 Delta variant: Prevention and vaccine development

Omicron overpowers key COVID antibody treatments in early tests

SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster. bioRxiv

mpact of SARS-CoV-2 delta variant (B.1.617.2) in surging second wave of COVID-19 and efficacy of vaccines in tackling the ongoing pandemic

SARS-CoV-2 delta variant: a persistent threat to the effectiveness of vaccines

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Res Sq

Neutralizing potency of COVID-19 vaccines against the SARS-CoV-2 Omicron (B.1.1.529) variant

Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 viruslike particles. medRxiv

Severe breakthrough COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era

Omicron variant and booster COVID-19 vaccines

mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing ac tivity against the SARS-CoV-2 Omicron variant

The emergence of new SARS-CoV-2 variant (Omicron) and increasing calls for COVID-19 boosters-the debate continues

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. medRxiv

Booster of mRNA-1273 vaccine reduces SARS-CoV-2 Omicron escape from neutralizing antibodies. medRxiv

Covid 19: US cases rise amid omicron fears but booster shots offer protection, experts say

COVID-19 vaccine hesitancyreasons and solutions to achieve a successful global vaccination campaign to tackle the ongoing pandemic

COVID-19 vaccine diplomacy and equitable access to vaccines amid ongoing pandemic

Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment

An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies

Drastic decline in sera neutralization against SARS-CoV-2 Omicron variant in Wuhan COVID-19 convalescents

Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost

Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant

SARSCOV-2 variants: differences and potential of immune evasion

Therapeutic options for coronavirus disease 2019 (COVID-19): where are we now? Curr Infect Dis Rep

COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health

The guidelines for the management of coronavirus disease 2019 developed by the US National Institutes of Health (NIH) that continue to be updated with newly emerging clinical data

Recent updates in experimental research and clinical evaluation on drugs for COVID-19 treatment

Antiviral pills could change pandemic's course

The emergence of powerful oral anti-COVID-19 drugs in the post-vaccine era

Daily briefing: Pfizer's COVID pill looks promising

Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports

Editorial: current status of oral antiviral drug treatments for SARS-CoV-2 infection in non-hospitalized patients

Contact tracing as a measure to combat COVID-19 and other infectious diseases highlights

Shooting at a moving target-effectiveness and emerging challenges for SARS-CoV-2 vaccine development. Vaccines (Basel)

Omicron: call for updated vaccines

Omicron: a drug developer's perspective

Investigating the aggressiveness of the COVID-19 Omicron variant and suggestions for possible treatment options

Transmission of Omicron (B.1.1.529) -SARS-CoV-2 Variant of Concern in a designated quarantine hotel for travelers: a challenge of elimination strategy of COVID-19. The Lancet Regional Health -Western Pacific

Preparing for Omicron as a covid veteran

Stopping coronavirus variants

Omicron: a failure to act with a global focus will continue the proliferation of new variants of covid-19

How to translate the knowledge of COVID-19 into the prevention of Omicron variants